Patient characteristics and outcomes
| Patient characteristics . | Treatment of FR . | Outcomes . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ID . | Age at diagnosis, y . | Age at FR, y . | Sex . | Prior therapies . | Previous PFS, mo* . | Line of therapy . | No. of cycles . | Toxicity . | Response . | Progression . | Follow-up after FR, mo . |
| 1 | 54 | 58 | Male | 2CDA | 58 | Second | 2 | Hypersensitivity to R | CRu | No | 29 |
| 2 | 48 | 53 | Male | 2CDA + splenectomy | 62 | Second | 4 | Unknown | Unknown | No | 33 |
| 3 | 46 | 59 | Male | 2CDA | 155 | Second | 4 | Unknown | Unknown | No | 26 |
| 4 | 36 | 41 | Male | 2CDA, 2CDA | 15, 52 | Third | 4 | None | CRu | No | 13 |
| 5 | 72 | 76 | Male | 2CDA, 2CDA | 5, 47 | Third | 3 Flu,6 rituximab | Interstitial lung disease | PR | Yes (31 months) | 57† |
| 6 | 46 | 49 | Male | 2CDA + splenectomy, 2CDA | 39, < 3 | Third | 4 | None | CRu | No | 57 |
| 7 | 53 | 66 | Male | 2CDA, 2CDA | 57, 97 | Third | 4 | None | CRu | No | 10 |
| 8 | 49 | 56 | Male | 2CDA, 2CDA | 6, 75 | Third | 4 | Herpes zoster | CR (MRD−) | No | 80 |
| 9 | 52 | 65 | Male | 2CDA, 2CDA | 51, 108 | Third | 4 | None | CR (MRD−) | No | 23 |
| 10 | 42 | 46 | Male | 2CDA, 2CDA, 2CDA | 9, 15, 21 | Fourth | 4 | None | CR (MRD−) | No | 78 |
| 11 | 37 | 55 | Male | IFN, 2CDA, Flu | 16, 135, 60 | Fourth | 4 | None | CRu | No | 39 |
| 12 | 52 | 75 | Female | IFN + splenectomy, DCF, 2CDA | 52, 86, 133 | Fourth | 4 | None | CRu | No | 66 |
| 13 | 54 | 82 | Female | IFN + spenectomy, DCF, 2CDA | 70, 258, < 3 | Fourth | 4 | None | CRu | No | 12 |
| 14 | 56 | 71 | Male | IFN, DCF, 2CDA, 2CDA | 5, 78, 46, 57 | Fifth | 4 | None | CRu | No | 65 |
| 15 | 46 | 68 | Male | IFN, IFN, DCF, 2CDA, Flu | 23, 11, 47, 77, 106 | Sixth | 4 | Herpes zoster | CRu | No | 35 |
| Patient characteristics . | Treatment of FR . | Outcomes . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ID . | Age at diagnosis, y . | Age at FR, y . | Sex . | Prior therapies . | Previous PFS, mo* . | Line of therapy . | No. of cycles . | Toxicity . | Response . | Progression . | Follow-up after FR, mo . |
| 1 | 54 | 58 | Male | 2CDA | 58 | Second | 2 | Hypersensitivity to R | CRu | No | 29 |
| 2 | 48 | 53 | Male | 2CDA + splenectomy | 62 | Second | 4 | Unknown | Unknown | No | 33 |
| 3 | 46 | 59 | Male | 2CDA | 155 | Second | 4 | Unknown | Unknown | No | 26 |
| 4 | 36 | 41 | Male | 2CDA, 2CDA | 15, 52 | Third | 4 | None | CRu | No | 13 |
| 5 | 72 | 76 | Male | 2CDA, 2CDA | 5, 47 | Third | 3 Flu,6 rituximab | Interstitial lung disease | PR | Yes (31 months) | 57† |
| 6 | 46 | 49 | Male | 2CDA + splenectomy, 2CDA | 39, < 3 | Third | 4 | None | CRu | No | 57 |
| 7 | 53 | 66 | Male | 2CDA, 2CDA | 57, 97 | Third | 4 | None | CRu | No | 10 |
| 8 | 49 | 56 | Male | 2CDA, 2CDA | 6, 75 | Third | 4 | Herpes zoster | CR (MRD−) | No | 80 |
| 9 | 52 | 65 | Male | 2CDA, 2CDA | 51, 108 | Third | 4 | None | CR (MRD−) | No | 23 |
| 10 | 42 | 46 | Male | 2CDA, 2CDA, 2CDA | 9, 15, 21 | Fourth | 4 | None | CR (MRD−) | No | 78 |
| 11 | 37 | 55 | Male | IFN, 2CDA, Flu | 16, 135, 60 | Fourth | 4 | None | CRu | No | 39 |
| 12 | 52 | 75 | Female | IFN + splenectomy, DCF, 2CDA | 52, 86, 133 | Fourth | 4 | None | CRu | No | 66 |
| 13 | 54 | 82 | Female | IFN + spenectomy, DCF, 2CDA | 70, 258, < 3 | Fourth | 4 | None | CRu | No | 12 |
| 14 | 56 | 71 | Male | IFN, DCF, 2CDA, 2CDA | 5, 78, 46, 57 | Fifth | 4 | None | CRu | No | 65 |
| 15 | 46 | 68 | Male | IFN, IFN, DCF, 2CDA, Flu | 23, 11, 47, 77, 106 | Sixth | 4 | Herpes zoster | CRu | No | 35 |
2CDA indicates cladribine; CRu, complete response unconfirmed, by normalization of peripheral blood counts, absence of abnormal circulating cells, and resolution of splenomegaly; PR, partial response; Flu, fludarabine; and DCF, deoxycoformycin (pentostatin).
Patients who relapsed within 3 months of therapy were considered to have refractory leukemia.
Patient relapsed 31 months after FR and died 57 months after FR from progressive HCL.